<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025944</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-RWS(CVH)</org_study_id>
    <nct_id>NCT04025944</nct_id>
  </id_info>
  <brief_title>Real World Study of Chronic Viral Hepatitis</brief_title>
  <official_title>Real World Study of Chronic Viral Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to collect and analyze clinical data of patients with chronic viral
      hepatitis in the real world, to investigate the long-term outcome of these patients and to
      optimize treatment options based on these data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic viral hepatitis is defined as infectious liver disease caused by persistent virus
      infection for more than six months. Sustained viral replication and ongoing liver
      inflammation can eventually lead to liver fibrosis/cirrhosis or even hepatocellular
      carcinoma. Chronic viral hepatitis infection causes at least 80% of all liver cancers.

      Though chronic viral hepatitis is a major global health concern, there is still a lack of
      evidence in high quality about the management of chronic viral hepatitis and the long-term
      outcome of patients. The concept of real-world data and research has been officially
      introduced into China since 2010. Real-world evidence, based on real-world data, can help
      practitioners have better understanding of the characteristics of the patients with different
      treatment strategies.

      This study is aimed to collect and analyze clinical data of patients with chronic viral
      hepatitis in the real world, to investigate the long-term outcome of these patients and to
      optimize treatment options based on these data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Virologic responses(for both chronic hepatitis B and C)</measure>
    <time_frame>24 weeks after treatment initiation</time_frame>
    <description>Sustained virological response （Able to sustain an undetectable viral load for a period）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serological responses(for chronic hepatitis B only)</measure>
    <time_frame>48 weeks after treatment initiation</time_frame>
    <description>Hepatitis B e antigen (HBeAg) seroconversion(HBeAg loss and presence of anti-HBe) and hepatitis B surface antigen(HBsAg) seroconversion (HBsAg loss and presence of anti-HBs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological responses(for both chronic hepatitis B and C)</measure>
    <time_frame>48 weeks after treatment initiation</time_frame>
    <description>Significant improvement in fibrosis was defined as a decrease in the Ishak score of at least 1 point; (the Ishak score describes six stages of fibrosis, 0 for No fibrosis and 6 for Cirrhosis; higher the Ishak score is, more severe the fibrosis is).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hepatitis, Chronic</condition>
  <arm_group>
    <arm_group_label>chronic hepatitis B</arm_group_label>
    <description>No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic hepatitis C</arm_group_label>
    <description>No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic viral hepatitis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent of patients.

          2. Evidence of persistent virus infection for greater than six months [hepatitis C
             virus(HCV) RNA positive, hepatitis B surface antigen(HBsAg) or hepatitis B virus(HBV)
             DNA positive]

        Exclusion Criteria:

          1. Serious psychiatric history, especially depression.

               -  Severe mental illness is defined as major depression or psychosis, suicide
                  attempts, hospitalization due to mental illness or a period of disability due to
                  mental illness.

          2. Patients with serious diseases of heart, lung, kidney, brain, blood and other
             important organs.

          3. Patients with malignant tumors (excluding those cured).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wenhong Zhang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiqi Yu, Doctor</last_name>
    <phone>13601637563</phone>
    <phone_ext>02152887969</phone_ext>
    <email>yyq19890619@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiqi Yu, doctor</last_name>
      <phone>13601637563</phone>
      <email>yyq19890619@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018 Jun 15;142(12):2471-2477. doi: 10.1002/ijc.31280. Epub 2018 Feb 9.</citation>
    <PMID>29388206</PMID>
  </reference>
  <reference>
    <citation>Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27. Review.</citation>
    <PMID>29599078</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Chief of department of infectious disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

